Literature DB >> 33164107

Transcriptional and post-transcriptional regulation of the pregnane X receptor: a rationale for interindividual variability in drug metabolism.

Tomas Smutny1, Lucie Hyrsova2, Albert Braeuning3, Magnus Ingelman-Sundberg4, Petr Pavek2.   

Abstract

The pregnane X receptor (PXR, encoded by the NR1I2 gene) is a ligand-regulated transcription factor originally described as a master regulator of xenobiotic detoxification. Later, however, PXR was also shown to interact with endogenous metabolism and to be further associated with various pathological states. This review focuses predominantly on such aspects, currently less covered in literature, as the control of PXR expression per se in the context of inter-individual differences in drug metabolism. There is growing evidence that non-coding RNAs post-transcriptionally regulate PXR. Effects on PXR have especially been reported for microRNAs (miRNAs), which include miR-148a, miR-18a-5p, miR-140-3p, miR-30c-1-3p and miR-877-5p. Likewise, miRNAs control the expression of both transcription factors involved in PXR expression and regulators of PXR function. The impact of NR1I2 genetic polymorphisms on miRNA-mediated PXR regulation is also discussed. As revealed recently, long non-coding RNAs (lncRNAs) appear to interfere with PXR expression. Reciprocally, PXR activation regulates non-coding RNA expression, thus comprising another level of PXR action in addition to the direct transactivation of protein-coding genes. PXR expression is further controlled by several transcription factors (cross-regulation) giving rise to different PXR transcript variants. Controversies remain regarding the suggested role of feedback regulation (auto-regulation) of PXR expression. In this review, we comprehensively summarize the miRNA-mediated, lncRNA-mediated and transcriptional regulation of PXR expression, and we propose that deciphering the precise mechanisms of PXR expression may bridge our knowledge gap in inter-individual differences in drug metabolism and toxicity.

Entities:  

Keywords:  CYP3A4; Gene expression; Non-coding RNA; Post-transcriptional regulation; Pregnane X receptor; microRNA

Year:  2020        PMID: 33164107     DOI: 10.1007/s00204-020-02916-x

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  94 in total

1.  Ochratoxin A induces CYP3A4, 2B6, 3A5, 2C9, 1A1, and CYP1A2 gene expression in primary cultured human hepatocytes: a possible activation of nuclear receptors.

Authors:  Imen Ayed-Boussema; Jean Marc Pascussi; Chiraz Zaied; Patrick Maurel; Hassen Bacha; Wafa Hassen
Journal:  Drug Chem Toxicol       Date:  2011-08-11       Impact factor: 3.356

Review 2.  Mechanisms and significance of nuclear receptor auto- and cross-regulation.

Authors:  Pia Bagamasbad; Robert J Denver
Journal:  Gen Comp Endocrinol       Date:  2010-03-23       Impact factor: 2.822

3.  Characterization of a novel PXR isoform with potential dominant-negative properties.

Authors:  Cyril Breuker; Chris Planque; Fatemeh Rajabi; Jean-Charles Nault; Gabrielle Couchy; Jessica Zucman-Rossi; Alexandre Evrard; Jovana Kantar; Eric Chevet; Paulette Bioulac-Sage; Jeanne Ramos; Eric Assenat; Dominique Joubert; Julie Pannequin; Frédéric Hollande; Jean Marc Pascussi
Journal:  J Hepatol       Date:  2014-05-02       Impact factor: 25.083

4.  Transcriptional regulation of the PXR gene: identification and characterization of a functional peroxisome proliferator-activated receptor alpha binding site within the proximal promoter of PXR.

Authors:  Sihem Aouabdi; Gordon Gibson; Nick Plant
Journal:  Drug Metab Dispos       Date:  2005-10-21       Impact factor: 3.922

Review 5.  Targeting xenobiotic receptors PXR and CAR in human diseases.

Authors:  Monimoy Banerjee; Delira Robbins; Taosheng Chen
Journal:  Drug Discov Today       Date:  2014-11-20       Impact factor: 7.851

6.  SXR, a novel steroid and xenobiotic-sensing nuclear receptor.

Authors:  B Blumberg; W Sabbagh; H Juguilon; J Bolado; C M van Meter; E S Ong; R M Evans
Journal:  Genes Dev       Date:  1998-10-15       Impact factor: 11.361

7.  Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction.

Authors:  G Bertilsson; J Heidrich; K Svensson; M Asman; L Jendeberg; M Sydow-Bäckman; R Ohlsson; H Postlind; P Blomquist; A Berkenstam
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

8.  The novel antibacterial compound walrycin A induces human PXR transcriptional activity.

Authors:  Alexandre Berthier; Frédérik Oger; Céline Gheeraert; Abdel Boulahtouf; Rémy Le Guével; Patrick Balaguer; Bart Staels; Gilles Salbert; Philippe Lefebvre
Journal:  Toxicol Sci       Date:  2012-02-07       Impact factor: 4.109

9.  A PXR-mediated negative feedback loop attenuates the expression of CYP3A in response to the PXR agonist pregnenalone-16α-carbonitrile.

Authors:  Ian Bailey; G Gordon Gibson; Kathryn Plant; Mark Graham; Nick Plant
Journal:  PLoS One       Date:  2011-02-02       Impact factor: 3.240

10.  Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes.

Authors:  Eric A Benson; Michael T Eadon; Zeruesenay Desta; Yunlong Liu; Hai Lin; Kimberly S Burgess; Matthew W Segar; Andrea Gaedigk; Todd C Skaar
Journal:  Front Pharmacol       Date:  2016-04-26       Impact factor: 5.810

View more
  2 in total

1.  Expression dynamics of pregnane X receptor-controlled genes in 3D primary human hepatocyte spheroids.

Authors:  Tomas Smutny; Veronika Bernhauerova; Lucie Smutna; Jurjen Duintjer Tebbens; Petr Pavek
Journal:  Arch Toxicol       Date:  2021-10-23       Impact factor: 5.153

2.  Patchouli Alcohol Modulates the Pregnancy X Receptor/Toll-like Receptor 4/Nuclear Factor Kappa B Axis to Suppress Osteoclastogenesis.

Authors:  Qian Lu; Chao Jiang; Jialong Hou; Hao Qian; Feifan Chu; Weiqi Zhang; Mengke Ye; Ziyi Chen; Jian Liu; Hanbing Yao; Jianfeng Zhang; Jiake Xu; Te Wang; Shunwu Fan; Qingqing Wang
Journal:  Front Pharmacol       Date:  2021-06-08       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.